3 Stocks Riding The AI Drug Discovery Shift In Pharma

AI did not just edge into drug discovery this year; it barged in through the front door, and OpenAI’s move on Orchestra Bio shows how fast the rules of pharmaceutical R&D can change. That shift creates a rare moment where investors risk watching a new wave of value creation from the sidelines. This article breaks down three stocks exposed to this AI drug discovery story and explains why they could matter for your portfolio.

The three stocks in this article are just a starting sample, and the full screen surfaced 40 more listed pharmaceutical and biotech companies using AI language in their drug discovery story that are not covered here but carry equally compelling narratives. To go beyond this short list, head straight into the AI-Enabled Pharmaceutical & Biotech R&D screener to identify, analyze, and focus on the AI R&D opportunities that best fit your own conviction and risk tolerance.

Tecan Group (SWX:TECN)

Overview: Tecan Group supplies automated lab instruments, software, and consumables that help biopharma and diagnostics customers run AI-ready research and testing workflows.

Operations: Tecan generates about CHF 501 million from its Partnering Business and CHF 378 million from its Life Sciences Business, with sales spread across the Americas, EMEA, and APAC.

Market Cap: CHF 2.9b

Tecan Group matters in this AI-enabled R&D screen because its lab automation gear and software often sit where pharma actually runs complex experiments and turns data into decisions.

"Tecan's focus on launching advanced, end-to-end workflow automation platforms (such as the Veya workstation and Duo Digital Dispenser) and proprietary software positions the company to benefit from increased digital transformation and data analytics in healthcare, potentially driving premium pricing and supporting margin expansion."

What really moves the needle from here is how one quiet shift in its mix between instruments, software, and services shapes future profitability.

That mix shift is the real hinge for Tecan Group, and the full narrative for Tecan Group shows how margins, customer stickiness, and AI exposure could all be quietly decoupling.

Chugai Pharmaceutical (TSE:4519)

Overview: Chugai Pharmaceutical develops, manufactures, and sells prescription medicines worldwide, focusing on biologics and specialty therapies across oncology, immunology, and rare diseases.

Operations: Chugai Pharmaceutical generates about ¥1.34t from pharmaceuticals, with roughly ¥486.19b reported in Japan and the remainder captured in segment adjustments.

Market Cap: ¥10.58t

Chugai Pharmaceutical matters in this AI-enabled R&D screen because it is a full-spectrum drug maker already wiring agentic AI directly into its discovery engine.

"Chugai Pharmaceutical has entered into a collaboration with Phylo to deploy Biomni Lab, an AI platform, across its drug discovery workflows with the goal of supporting research in areas such as single cell analysis, human genetics, disease biology and target evaluation."

The real test now is how one quiet shift in how those AI insights shape pipeline choices ends up feeding through to future earnings quality.

Those choices are already starting to matter for Chugai Pharmaceutical, and the full narrative for Chugai Pharmaceutical unpacks how AI driven pipeline shifts could quietly reshape earnings quality.

Cosmo (SWX:CMHC)

Overview: Cosmo N.V. is a Dublin based life sciences group that applies AI driven tools to develop gastroenterology drugs and health tech.

Operations: Cosmo currently reports about €103 million in revenue from its Pharmaceuticals segment, reflecting its focus on prescription treatments.

Market Cap: CHF884 million

Cosmo matters in this AI enabled pharmaceutical R&D screen because GI Genius brings artificial intelligence directly into clinical procedures and data rich workflows.

"The latest version of Cosmo's polyp detection software is now even more accurate, providing AI-generated information after the procedure, reaffirming Cosmo's leadership in AI-enhanced endoscopy."

What really determines how much of that AI promise reaches shareholders is one quiet shift in how recurring software revenue scales against ongoing R&D spend.

That shift is exactly what the full narrative for Cosmo examines in detail, revealing how Cosmo’s AI software economics could be quietly decoupling from its R&D burden.

Seeking Alternatives Before The Crowd?

Fresh ideas often move first. Breakout stories can gain momentum while they are still under the radar, and information decay can start to bite. To avoid reacting late, consider taking a closer look now.

• Identify stronger balance sheets by scanning the curated list of solid balance sheet and fundamentals (202 results) that filters for robust finances while this information is still timely.
• Look for earlier breakout momentum in income-focused opportunities using the hand picked 222 dividend fortresses designed to surface high-yield candidates before they attract wider attention.
• Monitor developing growth stories in future infrastructure through the focused 55 AI infrastructure stocks so potential compounding candidates are on your radar before they become widely followed.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com